PMID- 24552324
OWN - NLM
STAT- MEDLINE
DCOM- 20140225
LR  - 20220318
IS  - 1533-4406 (Electronic)
IS  - 0028-4793 (Linking)
VI  - 370
IP  - 8
DP  - 2014 Feb 20
TI  - Bevacizumab in glioblastoma--still much to learn.
PG  - 764-5
LID - 10.1056/NEJMe1313309 [doi]
FAU - Fine, Howard A
AU  - Fine HA
AD  - From the New York University (NYU) Cancer Institute, NYU Langone Medical Center, 
      New York.
LA  - eng
PT  - Comment
PT  - Editorial
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 2S9ZZM9Q9V (Bevacizumab)
RN  - 7GR28W0FJI (Dacarbazine)
RN  - YF1K15M17Y (Temozolomide)
SB  - IM
CON - N Engl J Med. 2014 Feb 20;370(8):699-708. PMID: 24552317
CON - N Engl J Med. 2014 Feb 20;370(8):709-22. PMID: 24552318
MH  - Angiogenesis Inhibitors/*therapeutic use
MH  - Antibodies, Monoclonal, Humanized/*therapeutic use
MH  - Bevacizumab
MH  - Brain Neoplasms/*drug therapy
MH  - Dacarbazine/*analogs & derivatives/therapeutic use
MH  - Female
MH  - Glioblastoma/*drug therapy
MH  - Humans
MH  - Male
MH  - Temozolomide
EDAT- 2014/02/21 06:00
MHDA- 2014/02/26 06:00
CRDT- 2014/02/21 06:00
PHST- 2014/02/21 06:00 [entrez]
PHST- 2014/02/21 06:00 [pubmed]
PHST- 2014/02/26 06:00 [medline]
AID - 10.1056/NEJMe1313309 [doi]
PST - ppublish
SO  - N Engl J Med. 2014 Feb 20;370(8):764-5. doi: 10.1056/NEJMe1313309.